Allele imputation for the killer cell immunoglobulin-like receptor KIR3DL1/S1.


Journal

PLoS computational biology
ISSN: 1553-7358
Titre abrégé: PLoS Comput Biol
Pays: United States
ID NLM: 101238922

Informations de publication

Date de publication:
02 2022
Historique:
received: 03 05 2021
accepted: 10 01 2022
revised: 04 03 2022
pubmed: 23 2 2022
medline: 13 4 2022
entrez: 22 2 2022
Statut: epublish

Résumé

Highly polymorphic interaction of KIR3DL1 and KIR3DS1 with HLA class I ligands modulates the effector functions of natural killer (NK) cells and some T cells. This genetically determined diversity affects severity of infections, immune-mediated diseases, and some cancers, and impacts the course of immunotherapies, including transplantation. KIR3DL1 is an inhibitory receptor, and KIR3DS1 is an activating receptor encoded by the KIR3DL1/S1 gene that has more than 200 diverse and divergent alleles. Determination of KIR3DL1/S1 genotypes for medical application is hampered by complex sequence and structural variation, requiring targeted approaches to generate and analyze high-resolution allele data. To overcome these obstacles, we developed and optimized a model for imputing KIR3DL1/S1 alleles at high-resolution from whole-genome SNP data. We designed the model to represent a substantial component of human genetic diversity. Our Global imputation model is effective at genotyping KIR3DL1/S1 alleles with an accuracy ranging from 88% in Africans to 97% in East Asians, with mean specificity of 99% and sensitivity of 95% for alleles >1% frequency. We used the established algorithm of the HIBAG program, in a modification named Pulling Out Natural killer cell Genomics (PONG). Because HIBAG was designed to impute HLA alleles also from whole-genome SNP data, PONG allows combinatorial diversity of KIR3DL1/S1 with HLA-A and -B to be analyzed using complementary techniques on a single data source. The use of PONG thus negates the need for targeted sequencing data in very large-scale association studies where such methods might not be tractable.

Identifiants

pubmed: 35192601
doi: 10.1371/journal.pcbi.1009059
pii: PCOMPBIOL-D-21-00820
pmc: PMC8896733
doi:

Substances chimiques

HLA-B Antigens 0
KIR3DL1 protein, human 0
KIR3DS1 protein, human 0
Receptors, KIR 0
Receptors, KIR3DL1 0
Receptors, KIR3DS1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1009059

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI158410
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI151549
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI151549
Pays : United States
Organisme : NHGRI NIH HHS
ID : R01 HG010297
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI128775
Pays : United States

Déclaration de conflit d'intérêts

I have read the journal’s policy and the authors of this manuscript have the following competing interests: Dr. Stephen Leslie is a partner with Peptide Groove LLP. All other authors have no competing interests to declare.

Références

PLoS One. 2012;7(7):e39991
pubmed: 22768326
J Virol. 2015 Jan;89(1):97-109
pubmed: 25320293
J Immunother Cancer. 2019 Mar 12;7(1):70
pubmed: 30871628
Nat Genet. 2011 Nov 06;43(12):1193-201
pubmed: 22057235
Front Immunol. 2012 Nov 01;3:326
pubmed: 23125843
Br J Dermatol. 2016 Feb;174(2):449-51
pubmed: 26286807
PLoS Pathog. 2014 Jan;10(1):e1003867
pubmed: 24453969
Nat Genet. 2002 Aug;31(4):429-34
pubmed: 12134147
Nature. 2011 Oct 23;479(7373):401-5
pubmed: 22020283
JHEP Rep. 2019 Oct 25;1(5):353-360
pubmed: 32039386
Mol Biol Evol. 2021 May 19;38(6):2582-2596
pubmed: 33616658
Blood. 2008 Jul 15;112(2):435-43
pubmed: 18385451
J Infect Dis. 2021 Jul 2;224(1):175-183
pubmed: 33165540
J Virol. 2011 Jun;85(12):5949-60
pubmed: 21471235
AIDS. 2018 Apr 24;32(7):841-850
pubmed: 29280757
J Immunol. 2021 Feb 15;206(4):849-860
pubmed: 33441440
Nucleic Acids Res. 2015 Jan;43(Database issue):D423-31
pubmed: 25414341
Am J Hum Genet. 2015 Oct 1;97(4):593-607
pubmed: 26430804
Front Immunol. 2019 Jul 16;10:1646
pubmed: 31379844
J Virol. 2015 May;89(10):5213-21
pubmed: 25740999
Am J Hum Genet. 2008 Jan;82(1):48-56
pubmed: 18179884
Tissue Antigens. 2013 Dec;82(6):397-404
pubmed: 24498996
Front Immunol. 2018 Dec 04;9:2843
pubmed: 30564239
Gene. 2017 Dec 30;637:219-229
pubmed: 28942035
J Exp Med. 2006 Mar 20;203(3):633-45
pubmed: 16533882
J Leukoc Biol. 2010 Nov;88(5):905-12
pubmed: 20664023
Hum Immunol. 2021 Jul;82(7):523-531
pubmed: 33812704
J Immunol. 2007 Jan 1;178(1):33-7
pubmed: 17182537
Genes Immun. 2016 Apr;17(3):199-202
pubmed: 26866467
Semin Hematol. 2020 Oct;57(4):167-174
pubmed: 33256909
Front Immunol. 2017 May 26;8:581
pubmed: 28603523
Sci Rep. 2020 Mar 24;10(1):5267
pubmed: 32210306
Immunology. 2017 Mar;150(3):248-264
pubmed: 27779741
Tissue Antigens. 2000 Oct;56(4):313-26
pubmed: 11098931
Science. 1995 Apr 21;268(5209):405-8
pubmed: 7716543
J Clin Oncol. 2017 Jul 10;35(20):2268-2278
pubmed: 28520526
J Virol. 2011 Jun;85(12):5970-4
pubmed: 21471246
Nat Methods. 2019 Jan;16(1):88-94
pubmed: 30559433
Ann Neurol. 2009 Jun;65(6):658-66
pubmed: 19630074
Nat Immunol. 2018 Aug;19(8):800-808
pubmed: 30026479
J Clin Oncol. 2016 Jul 20;34(21):2443-51
pubmed: 27069083
J Virol. 2019 Aug 28;93(18):
pubmed: 31270222
Biol Blood Marrow Transplant. 2009 Nov;15(11):1366-75
pubmed: 19822295
Eur J Immunol. 2016 Jun;46(6):1511-7
pubmed: 26990677
J Clin Invest. 2018 May 1;128(5):1903-1912
pubmed: 29461980
Blood. 2010 Apr 15;115(15):3162-5
pubmed: 20124216
Exp Hematol. 2017 Feb;46:38-47
pubmed: 27765614
Int J Mol Sci. 2021 Mar 31;22(7):
pubmed: 33807229
PLoS One. 2012;7(11):e47491
pubmed: 23139747
Front Immunol. 2021 May 07;12:674778
pubmed: 34025673
J Infect Dis. 2005 Jul 1;192(1):162-5
pubmed: 15942906
Nat Immunol. 2016 Sep;17(9):1067-74
pubmed: 27455421
J Exp Med. 2005 Apr 4;201(7):1069-75
pubmed: 15809352
PLoS One. 2013 Jun 06;8(6):e64683
pubmed: 23762245
Clin Rheumatol. 2017 Oct;36(10):2261-2266
pubmed: 28801811
PLoS Comput Biol. 2021 Aug 2;17(8):e1008904
pubmed: 34339413
Oncoimmunology. 2017 May 19;6(7):e1330235
pubmed: 28811973
Nature. 2019 Jun;570(7762):514-518
pubmed: 31217584
Am J Hum Genet. 2016 Aug 4;99(2):375-91
pubmed: 27486779
Clin Cancer Res. 2019 May 15;25(10):3026-3034
pubmed: 30765392
Nat Genet. 2016 Jul;48(7):811-6
pubmed: 27270109
J Exp Med. 2016 May 2;213(5):791-807
pubmed: 27045007
Clin Exp Immunol. 2016 Mar;183(3):419-30
pubmed: 26439909
Kidney Int. 2021 May;99(5):1140-1148
pubmed: 33359499
Arthritis Rheum. 2010 Apr;62(4):1000-6
pubmed: 20131260
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3053-8
pubmed: 18287063
PLoS One. 2016 Oct 10;11(10):e0163973
pubmed: 27723813
Cancer Immunol Res. 2018 Jun;6(6):745-754
pubmed: 29695383
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Curr Opin Immunol. 2018 Feb;50:102-111
pubmed: 29413815
Methods Mol Biol. 2016;1393:141-5
pubmed: 27033224
Crit Rev Immunol. 2013;33(3):203-18
pubmed: 23756244
Nat Genet. 2007 Sep;39(9):1092-9
pubmed: 17694054
Am J Transplant. 2011 Jun;11(6):1302-7
pubmed: 21486386
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
J Exp Med. 1994 Aug 1;180(2):537-43
pubmed: 8046332
PLoS One. 2018 Apr 12;13(4):e0195778
pubmed: 29649328
Blood. 2010 Sep 23;116(12):2033-9
pubmed: 20562327
Oncoimmunology. 2021 Jun 14;10(1):1936392
pubmed: 34178429
J Immunol. 2016 Apr 15;196(8):3398-410
pubmed: 26962229
Arthritis Rheumatol. 2015 Nov;67(11):2957-65
pubmed: 26238044
Pharmacogenomics J. 2018 May 22;18(3):367-376
pubmed: 28440342
J Infect Dis. 2013 Oct 15;208(8):1250-4
pubmed: 23922366
Eur J Immunol. 2021 Jul;51(7):1566-1579
pubmed: 33899224
Hum Mol Genet. 2019 Jun 15;28(12):2078-2092
pubmed: 30590525
Genome Res. 2009 May;19(5):757-69
pubmed: 19411600
Exp Hematol. 2015 Dec;43(12):1015-1018.e1
pubmed: 26306453
PLoS Pathog. 2008 Sep 19;4(9):e1000160
pubmed: 18802459
Blood Adv. 2020 Oct 13;4(19):4955-4964
pubmed: 33049053
PLoS Comput Biol. 2013;9(2):e1002877
pubmed: 23459081
J Immunol. 2019 Sep 15;203(6):1629-1635
pubmed: 31405953
Pharmacogenomics J. 2014 Apr;14(2):192-200
pubmed: 23712092
J Immunol. 2020 Sep 1;205(5):1323-1330
pubmed: 32709660
J Clin Invest. 2008 Mar;118(3):1017-26
pubmed: 18246204
Blood Adv. 2021 Apr 13;5(7):2003-2011
pubmed: 33843984
J Immunol. 2011 Sep 1;187(5):2162-71
pubmed: 21804024
Genet Epidemiol. 2011 Feb;35(2):85-92
pubmed: 21254215
Front Immunol. 2017 Jun 12;8:675
pubmed: 28659916
Nature. 2021 Feb;590(7845):290-299
pubmed: 33568819
Nat Genet. 2007 Jun;39(6):733-40
pubmed: 17496894
Immunogenetics. 2017 Aug;69(8-9):547-556
pubmed: 28699110
Am J Transplant. 2017 Aug;17(8):2192-2199
pubmed: 28375571
J Immunol. 2011 Jul 1;187(1):11-9
pubmed: 21690332

Auteurs

Genelle F Harrison (GF)

Division of Biomedical Informatics and Personalized Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.
Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.

Laura Ann Leaton (LA)

Division of Biomedical Informatics and Personalized Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.
Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.

Erica A Harrison (EA)

Independent Researcher, Broomfield, Colorado, United States of America.

Katherine M Kichula (KM)

Division of Biomedical Informatics and Personalized Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.
Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.

Marte K Viken (MK)

Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.

Jonathan Shortt (J)

Division of Biomedical Informatics and Personalized Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.

Christopher R Gignoux (CR)

Division of Biomedical Informatics and Personalized Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.

Benedicte A Lie (BA)

Department of Immunology, University of Oslo and Oslo University Hospital, Oslo, Norway.
Department of Medical Genetics, University of Oslo and Oslo University Hospital, Oslo, Norway.

Damjan Vukcevic (D)

School of Mathematics and Statistics, University of Melbourne, Parkville, Victoria, Australia.
Melbourne Integrative Genomics, University of Melbourne, Parkville, Victoria, Australia.

Stephen Leslie (S)

School of Mathematics and Statistics, University of Melbourne, Parkville, Victoria, Australia.
Melbourne Integrative Genomics, University of Melbourne, Parkville, Victoria, Australia.
School of BioSciences, University of Melbourne, Parkville, Victoria, Australia.

Paul J Norman (PJ)

Division of Biomedical Informatics and Personalized Medicine, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.
Department of Immunology and Microbiology, University of Colorado, Anschutz Medical Campus, Aurora, Colorado, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH